Giant cell tumor of bone (GCTB) is a benign, locally destructive neoplasm, with tumors comprised of mesenchymal fibroblast-like stromal cells; monocytic, mononuclear cells of myeloid lineage; and the characteristic osteoclast-like, multinucleated giant cells. Hampering the study of the complex interaction of its constituent cell types is the propensity of longstanding, repeatedly passaged cell ...

Giant-cell tumor of the bone (GCTB) is a rare neoplasm that affects young adults. The tumor is generally benign but sometimes can be locally aggressive. There are no standardized approaches to the treatment of GCTB. Recently, the RANKL inhibitor denosumab has shown activity in this tumor type. We present the case of a young female who presented with locally advanced disease and was successfully...

Plant-based transient overexpression systems enable rapid and scalable production of subunit vaccines. Previously, we have shown that cholera toxin B subunit (CTB), an oral cholera vaccine antigen, is N-glycosylated upon expression in transgenic Nicotiana benthamiana. Here, we found that overexpression of aglycosylated CTB by agroinfiltration of a tobamoviral vector causes massive tissue necros...

Background: Giant cell tumor of bone (GCTB) is a relatively common benign tumor, accounting for 4–9.5 % all primary neoplasms. Localization GCTB one the most important differential diagnostic criteria, since affects certain parts skeleton. Until now, surgical treatment was considered method choice in GCTB. However, recent years, denosumab, genetically engineered drug, has been widely used to tr...

Purpose or Learning Objective: Our aim was (1) to evaluate the value of computed tomography (CT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for monitoring denosumab therapy giant cell tumor bone (GCTB); (2) describe findings at diagnosis during treatment; (3) offer an overview good poor response, relapse, therapeutic complications.

Giant cell tumour of bone (GCTB) is a benign osteolytic tumour with three main cellular components: multinucleated osteoclast-like giant cells, mononuclear spindle-like stromal cells (the main neoplastic components) and mononuclear cells of the monocyte/macrophage lineage. The giant cells overexpress a key mediator in osteoclastogenesis: the RANK receptor, which is stimulated in turn by the cyt...

BACKGROUND Various treatments of giant cell tumor of bone (GCTB) included in curettages and resections and with adjuvant are exerted, but the best treatment is controversial. The aim of the study was the identification of individual risk factors after various treatments in GCTB. METHODS A total of 179 patients treated for GCTB between 1998 and 2010 were concluded in the retrospective study. A...

Materials and Methods: The silver (Ag), cobalt (Co), chromium (Cr), iron (Fe), mercury (Hg), rubidium (Rb), antimony (Sb), selenium (Se), and zinc (Zn) content and Co/Ag, Cr/Ag, Fe/Ag, Hg/Ag, Sb/Ag, Se/Ag, Co/Rb, Cr/Rb, Fe/Rb, Hg/Rb, Sb/ Rb, Se/Rb, Co/Zn, Cr/Zn, Fe/Zn, Hg/Zn, Sb/Zn, and Se/Zn ratios were estimated in normal bone samples from 27 patients with intact bone (12 females and 15 males...

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the source is credited. DOI 10.3109/17453674.2014.1002345 A 52-year-old man presented at our tertiary referral center for orthopedic oncology with progressive pain in the left hip and leg. Co...

Giant cell tumor of bone (GCTB) is a benign osteolytic with an aggressive course, affects the metaphyseal and epiphyseal areas bone. GCTB RANKL-positive tumor. Therefore, RANKL promising target for directed influence on processes resorption. Objective. To analyze world own experience denosumab using in treatment patients giant Methods. The search publications electronicsystems was carried out G...